DESCRIPTION (provided by applicant): Intensive glucose control in type 1 diabetes mellitus (T1DM) is associated with clear health benefits. However, maintaining near-normal glycemia remains an elusive goal for most patients, in large part owing to the risk of low glucose levels (hypoglycemia). T1DM patients are susceptible to hypoglycemia due to defective counterregulatory responses (CR) characterized by: 1) deficient glucagon release during impending hypoglycemia; 2) additional hypoglycemia-associated autonomic failure (HAAF) and exercise-associated autonomic failure (EAAF) that blunt the sympathoadrenal responses to hypoglycemia following repeated episodes of hypoglycemia or exercise as well as degrading other CR; and 3) hypoglycemia unawareness, lowering the threshold for symptoms that trigger behavioral responses (e.g. eating). Thus, the risk of hypoglycemia in T1DM impedes ideal insulin treatment and leads to suboptimal glycemic control. Our lab has explored a new approach of enhancing CR by translating mechanisms responsible for HAAF/EAAF into potential therapeutics to modulate the CR to hypoglycemia. We have previously demonstrated that HAAF can be prevented in T1DM patients by opioid receptor blockade. Since adrenergic activation has also a modulatory effect on hypoglycemia CR, we thus hypothesize that a common mechanism linking opioidergic and adrenergic systems is responsible for the development of HAAF and EAAF. Our specific aims are to 1. Examine whether activation of ?-opioid receptors, and/or adrenergic receptors, regulate HAAF in humans, 2. Establish the components of the adrenergic response responsible for modulating HAAF/EAAF and their association with the opioidergic system, and 3. Perform a preliminary clinical trial to examine the efficacy of chronic opioid receptor blockade in preventing HAAF in patients with T1DM. Correction or improvement of hypoglycemia counterregulation and restoring hypoglycemia awareness in patients with T1DM would represent an enormous step forward in the management of these patients, including preventing morbidities or death.
|Effective start/end date||2/1/08 → 3/31/20|
- Endocrinology, Diabetes and Metabolism
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.